New Treatment for Lung Cancer Shows Promise Non-Invasive, Inhalable Powder Increases Survival Rates
Arlington, Va. — A new inhalable dry powder treatment for
Lung cancer is the second most common type of cancer in the
U.S., accounting for more deaths than breast, prostate and colon
cancer combined, according to the Centers for Disease Control and
Lead researcher Raimar Löbenberg and his colleagues Warren
Finlay and Wilson Roa from the University of
Results showed that the inhalable dry powder was more effective than using the IV or solution. In the study, more than 80 percent of the mice survived for more than 90 days and more than 70 percent survived for 140 days. None of the mice treated with the IV injection or solution survived past 50 days.
“Current lung cancer treatments can be grueling and take a significant toll on the patient,” said Löbenberg. “Our results show that this treatment method may not only increase someone’s survival rate but could also potentially be less toxic to the body.”
The inhalable dry powder was also more effective than the IV injection in reducing the amount and size of tumors. Large tumor masses were seen in the lungs of those animals that were not treated or treated with the IV injection or solution. Animals treated with the inhalable dry powder showed fewer and much smaller tumors.
For the first time, FIP’s
Learn more about the meeting and global health from leading
scientists in this webisode
# # #
About AAPS: The American Association of Pharmaceutical
Scientists is a professional, scientific society of approximately
12,000 members employed in academia, industry, government and other
research institutes worldwide. For more information, please visit
About FIP: The International Pharmaceutical Federation is the
global federation of national associations representing two million
pharmacists and pharmaceutical scientists from around the world.
For more information, please visit
Hillarie Turner firstname.lastname@example.org@ecius.net> 202-296-2002
Posted: November 2010